Electronic brachytherapy as adjuvant therapy for early stage breast cancer: a retrospective analysis
Authors Dooley W, Wurzer J, Megahy M, Schreiber G, Roy T, Proulx G, Laduzinsky S, Lane S, Dalzell J, Dowlatshahi K, Simmons D, Thropay J, Ahuja H, Beitsch P, Holt R, Lee C
Published 12 January 2011 Volume 2011:4 Pages 13—20
Review by Single-blind
Peer reviewer comments 2
William C Dooley1, James C Wurzer2, Mohamed Megahy3, Gary Schreiber4, Tapan Roy5, Gary Proulx6, Susan Laduzinsky7, Steven Lane8, James Dalzell9, Kambiz Dowlatshahi10, Dwelvin Simmons11, John P Thropay12, Harish Ahuja13, Peter Beitsch14, Randall W Holt15, Charles A Lee16
1Oklahoma University Health Sciences Center, Oklahoma City, OK, USA; 2Atlanticare, Egg Harbor Township, NJ, USA; 3Maryville Oncology, Maryville, IL, USA; 4Swedish Covenant Hospital, Chicago, IL, USA; 5Cape Girardeau Cancer Center, Cape Girardeau, MO, USA; 6Exeter Hospital, Exeter, NH, USA; 7St. Elizabeth's Medical Center, Swansea, IL, USA; 8Brockton Hospital, Brockton, MA, USA; 9Nazha Cancer Center, Northfield, NJ, USA; 10Rush University Medical Center, Chicago, IL, USA; 11Florida Radiation Oncology Group, Jacksonville, FL, USA; 12Beverly Oncology and Imaging Center, Montebello, CA, USA; 13Aspirus Cancer Center, Wausau, WI, USA; 14Dallas Surgical Group, Dallas, TX, USA; 15Pacific Crest Medical Physics, Chico, CA, USA; 16Gulf Coast Cancer Treatment Center, Panama City, FL, USA
Purpose: This multicenter, retrospective study evaluated treatment and clinical outcomes of patients with early stage breast cancer who received adjuvant high-dose rate (HDR) electronic brachytherapy (EBT) treatment post-lumpectomy using the Axxent® EBT system. Dosimetric data from the EBT treatment plans were compared with those based on iridium-192 HDR brachytherapy.
Material and methods: Medical records of 63 patients with early stage breast cancer (Tis, T1a, T1b, T1c, and T2) who were treated post-lumpectomy with EBT alone or in combination with external beam radiation therapy were reviewed. The prescribed EBT dose was 34 Gy (10 fractions over 5 days, 3.4 Gy each) to 1 cm from the balloon surface. Dosimetry data from 12 patients were compared with these of treatment plans using an iridium-192 source prepared for the same 12 patients.
Results: The majority of patients (90.5%) were older than 50 years and had one or more risk factors for breast cancer (80.6%). Tumor sizes were 0.1 cm to 3.5 cm (mean 1.3 cm). Median follow-up was 7 months (1 to 18 months) post-EBT. Balloon applicators were implanted 0 to 85 days (mean 13.4 days) post-lumpectomy/re-excision. The most common adverse events were erythema, rash dermatitis, and pain or breast tenderness. No recurrences were reported. Dosimetric analyses demonstrated comparable target coverage, increased high-dose regions, and a significantly reduced dose to the ipsilateral breast and lungs as well as the heart with EBT as compared with the iridium-192 treatment plans.
Conclusion: This retrospective, multicenter study showed that postsurgical adjuvant radiation therapy for early stage breast cancer can be administered using the EBT system with similar toxicity outcomes to those reported with iridium-192 brachytherapy. EBT offers a convenient, portable, nonisotope alternative to HDR brachytherapy using iridium-192.
Keywords: electronic brachytherapy, breast cancer, radiation therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]